Wegovy vs Zepbound has become one of the hottest comparisons in weight loss treatments today. Both are weekly injectable medications designed to help patients lose significant amounts of weight, but they are built differently. Wegovy is powered by semaglutide, while Zepbound uses tirzepatide, a newer drug that targets two hormone pathways instead of one.

If you’re trying to decide between Wegovy vs Zepbound, it helps to understand how each works, their clinical results, and what side effects to expect. While both deliver strong outcomes, there are key differences in FDA approval, average weight loss, and long-term benefits. Below, you’ll find a side-by-side breakdown to help you compare the two treatments clearly.

Comparison Table of Wegovy vs Zepbound

Feature	Wegovy	Zepbound
Active Ingredient	Semaglutide	Tirzepatide
FDA Approval	Chronic Weight Management (2021)	Chronic Weight Management (2023)
Mechanism of Action	GLP-1 receptor agonist	Dual GLP-1 & GIP receptor agonist
Dosage	Weekly injection, 0.25–2.4 mg	Weekly injection, 2.5–15 mg
Primary Use	Obesity treatment & weight loss	Obesity treatment & weight loss
Average Weight Loss	15% of body weight in clinical trials	Up to 25% of body weight in trials
Side Effects	Nausea, vomiting, diarrhea, fatigue	Similar GI effects, sometimes stronger
Cardiovascular Benefits	Proven reduction in heart risk	Still being studied, early signs positive
Cost	~$1,300+/month (varies by insurance)	~$1,000+/month (varies by insurance)
Manufacturer	Novo Nordisk	Eli Lilly

Key Takeaways for Wegovy vs Zepbound

• Wegovy is well-established and has strong FDA backing for weight management.

• Zepbound is newer but shows even greater weight loss results in clinical trials.

• Both share similar side effects and weekly dosing, though Zepbound may cause stronger GI issues.

• Cost and insurance coverage vary, with Wegovy often slightly more expensive.

---

👉 Still comparing weight loss medications? Explore our Ozempic vs Zepbound Comparison or view our Wegovy products here at RocketMeds.